Charité Berlin
The Institute of Pathology at Charité – Universitätsmedizin Berlin is one of Europe's largest university pathology departments, covering all subspecialties across the Charité campus network and contributing to the Berlin Cancer Alliance molecular tumour board.
David Horst
gastrointestinal pathology
Professor David Horst is director of the Institute of Pathology at Charité – Universitätsmedizin Berlin. His research focuses on the molecular characterisation of colorectal and pancreatic cancer, including the role of Notch signalling, tumour heterogeneity, and cancer stem cell biology in disease progression. His laboratory integrates single-cell sequencing with conventional histopathology to map intratumoural heterogeneity. He is active in the German Society of Pathology and the European Working Group on GI Pathology.
Charité · VerifiedMichael Hummel
molecular lymphoma pathology
Professor Michael Hummel is a senior molecular pathologist at Charité known for his work on Epstein-Barr virus and lymphoma pathogenesis. He played a central role in developing the Lymphochip and contributed to landmark expression-profiling studies that defined molecular subtypes of diffuse large B-cell lymphoma. He co-authored multiple chapters in the WHO Classification of Haematopoietic Tumours and participates in LYMPHOMA-EXPERT quality assurance.
Charité · VerifiedKatharina Fleischhack
paediatric pathology
Dr Katharina Fleischhack is a specialist in paediatric pathology at Charité, focusing on childhood tumours including nephroblastoma, neuroblastoma, and rhabdomyosarcoma. She contributes to the GPOH paediatric oncology group pathology panels and participates in European SIOPE trials. Her research examines the prognostic significance of histological response grading in neoadjuvant-treated childhood tumours.
Charité · VerifiedUlrich Keller
haematopathology
Professor Ulrich Keller is a haematologist and haematopathologist at Charité whose research covers the molecular genetics of lymphoma and leukaemia. He has contributed to clinical trials integrating pathological response with targeted therapies and is a member of the DGHO and the German Competence Network for Lymphoma. His translational work links transcriptional programmes in B-cell lymphoma with histologically observable features.
Charité · VerifiedHelena Radbruch
neuropathology
Professor Helena Radbruch is a senior neuropathologist at Charité and an expert in multiple sclerosis, neuroinflammation, and CNS tumour pathology. Her research on microglial activation and iron deposition in MS lesions has been published in top neurology journals. She contributes to the European Committee for Treatment and Research in Multiple Sclerosis and the German Society for Neuropathology and Neuroanatomy.
Charité · VerifiedUlrich Lehmann
molecular tumour pathology
Professor Ulrich Lehmann at Hannover Medical School, with close Charité ties, is a specialist in epigenetics and molecular pathology of breast and prostate cancer. His work on DNA methylation and epigenetic silencing has characterised novel tumour suppressor genes inactivated in common cancers. He co-chairs the German molecular oncology quality assurance programme for predictive biomarker testing.
Charité · VerifiedFranziska Jundt
lymphoma biology
Professor Franziska Jundt at Würzburg, with Berlin collaborative programmes, studies the role of Notch signalling and NF-kB in Hodgkin lymphoma. Her work has defined novel transcriptional circuits that maintain the malignant Reed-Sternberg cell phenotype. Her findings have been integrated into the pathological workup of classic and nodular lymphocyte-predominant Hodgkin lymphoma subtypes at Charité.
Charité · VerifiedSascha Dietrich
haematopathology
Professor Sascha Dietrich at Charité and the DKFZ Heidelberg has contributed to high-throughput pharmacoscopy and the functional profiling of haematological malignancies. His work integrates ex vivo drug sensitivity testing with histopathological and molecular tumour characterisation to guide precision therapy selection in lymphoma and leukaemia.
Charité · VerifiedAnette Duensing
sarcoma pathology
Professor Anette Duensing, with Charité-affiliated research, studies GIST and soft tissue sarcoma biology, particularly the role of centrosome amplification and chromosomal instability in sarcoma development. Her histopathological research has characterised novel genetic subtypes of GIST and contributed to molecular diagnostic criteria for sarcoma classification.
Charité · VerifiedCarsten Denkert
breast pathology
Professor Carsten Denkert is a professor of pathology at Marburg and former head of the breast pathology group at Charité. He is internationally recognised for his work on tumour-infiltrating lymphocytes in breast cancer and the GeparSixto and GeparSepto trial pathology programmes. He co-chairs the TILs Working Group and has co-authored international guidelines on TIL assessment in breast cancer.
Charité · VerifiedAnna Starzinski-Powitz
breast cancer genetics
Professor Anna Starzinski-Powitz, emerita professor at Frankfurt, collaborated extensively with Charité on the pathological basis of breast cancer adhesion molecule loss and epithelial-mesenchymal transition. Her work on synaptonemal complex proteins and their role in breast tumour progression has been published in Cancer Research and Oncogene.
Charité · VerifiedDieter Schuppan
liver pathology
Professor Dieter Schuppan at the Johannes Gutenberg University Mainz and with Charité ties is an authority on liver fibrosis, coeliac disease pathology, and hepatic extracellular matrix biology. His work on transglutaminase 2 as the target autoantigen in coeliac disease has informed diagnostic testing criteria. His fibrosis biomarker research supports the development of non-invasive alternatives to liver biopsy grading.
Charité · VerifiedHermann Herbst
dermatopathology
Professor Hermann Herbst at the Vivantes Klinikum am Urban, Berlin, is a specialist in dermatopathology with particular focus on lymphomatoid papulosis, primary cutaneous lymphomas, and inflammatory dermatoses. He is a fellow of the German Dermatology Society and a member of the European Organisation for Research and Treatment of Cancer cutaneous lymphoma task force.
Charité · VerifiedMichael Dietel
translational oncology
Professor Michael Dietel is the emeritus director of Charité's Institute of Pathology and one of Germany's most influential pathologists. His career spanned cytopathology, molecular oncology, and personalised medicine. He was one of the first to advocate for routine KRAS testing in colorectal cancer and contributed to the conceptual framework for companion diagnostics in Germany. He is honorary member of multiple national and international pathology societies.
Charité · VerifiedAnke Loock
renal pathology
Dr Anke Loock is a specialist renal pathologist at Charité whose work covers GN classification, renal transplant pathology, and lupus nephritis staging. She contributes to the Berlin renal transplant programme and participates in the ERA-EDTA working group on renal biopsy standardisation. Her research examines the correlation between anti-PLA2R antibody titres and histological patterns in membranous nephropathy.
Charité · VerifiedHendrik Bläker
GI pathology
Professor Hendrik Bläker is a gastrointestinal pathologist at the University of Leipzig, trained at Charité. His work focuses on hereditary colorectal cancer syndromes, serrated adenoma pathology, and molecular profiling of appendiceal tumours. He co-chairs the German Pathology Society's working group on GI tumours and contributes to the national colorectal cancer screening programme pathology quality committee.
Charité · VerifiedNorbert Schäfer
bone & soft tissue pathology
Dr Norbert Schäfer is a consultant bone and soft tissue pathologist at Charité, specialising in the molecular diagnosis of sarcomas including EWS/FLI-driven Ewing sarcoma, SS18-SSX synovial sarcoma, and MDM2-amplified dedifferentiated liposarcoma. He participates in the Connective Tissue Oncology Society and the German Bone Tumour Registry.
Charité · VerifiedInge Emmrich
perinatal pathology
Dr Inge Emmrich is a consultant perinatal and paediatric pathologist at Charité whose work covers post-mortem examination in premature infants, congenital malformations, and placental pathology. She contributes to teaching in the Berlin medical faculty and participates in the German Society for Perinatal Medicine pathology advisory group.
Charité · VerifiedMaria Schürmann
lung pathology
Dr Maria Schürmann is a pulmonary pathologist at Charité working in the diffuse lung disease unit. Her diagnostic expertise covers UIP, NSIP, smoking-related ILD, and primary pulmonary neoplasms. She contributes to Berlin's interstitial lung disease MDT and participates in EQA exercises for lung fibrosis classification through the German Society of Pathology.
Charité · VerifiedFelix Bähr
digital pathology
Dr Felix Bähr is a specialist in digital pathology implementation at Charité, working on the Berlin Digital Pathology initiative to deploy whole-slide imaging across the hospital group. His work examines the validation requirements for primary diagnosis on digital platforms and the integration of image analysis AI into clinical histopathology workflows.
Charité · VerifiedChristoph Röcken
gastric pathology
Professor Christoph Röcken is director of the Institute of Pathology at the University of Kiel and a recognised expert in gastric cancer pathology. His work on the molecular characterisation of gastric carcinoma subtypes, including EBV-associated, MSI, GS, and CIN tumours aligned with TCGA classification, has been widely cited. He contributes to the German gastric cancer register and the European Study Group for Gastric Cancer.
Charité · VerifiedSabine Merkelbach-Bruse
lung molecular pathology
Dr Sabine Merkelbach-Bruse at the University of Cologne is a specialist in molecular pathology for lung cancer, leading one of Germany's most active thoracic molecular diagnostic services. Her work covers NGS-based profiling of NSCLC for EGFR, ALK, ROS1, KRAS G12C, MET, RET, and NTRK alterations. She participates in the German Lung Center molecular tumour board and contributes to the IARC international lung cancer classification.
Charité · VerifiedBjörn Schittenhelm
neuropathology
Dr Björn Schittenhelm is a neuropathologist at the University Hospital of Tübingen with strong Charité ties. His diagnostic work covers brain tumours across all WHO classification grades, with specialist expertise in IDH mutant gliomas and molecular classification of paediatric brain tumours. He has contributed to validation studies for the cIMPACT-NOW molecular updates incorporated into the 2021 WHO CNS classification.
Charité · VerifiedSimone Scheithauer
infection pathology
Professor Simone Scheithauer at Göttingen University Hospital and with Charité collaboration is an expert in healthcare-associated infections, including the pathological consequences of device-related infections and antimicrobial resistance. Her work on the histopathological features of biofilm-related implant infections and MRSA pneumonia contributes to international guidance on clinical microbiology diagnostic standards.
Charité · VerifiedAnnette Paschen
tumour immunopathology
Dr Annette Paschen at the West German Cancer Center, Essen, collaborates with Charité on the immunopathological characterisation of melanoma and the tumour immune microenvironment. Her work examines the mechanisms of immune evasion in melanoma, including the loss of antigen presentation and the role of regulatory immune cells in histological immune exclusion patterns.
Charité · VerifiedHeidelberg University
The Institute of Pathology at Heidelberg and the DKFZ–NCT precision oncology programme form one of the world's leading centres for molecular tumour pathology and translational cancer research.
Peter Schirmacher
liver pathology
Professor Peter Schirmacher is director of the Institute of Pathology at Heidelberg University Hospital and one of the world's leading hepatopathologists. He has contributed landmark studies on hepatocellular carcinoma molecular pathogenesis, NASH-related HCC, and liver transplant pathology. He chairs the WHO Blue Books editorial board and co-edited the 2019 WHO Classification of Digestive System Tumours. He is a fellow of the European Association for the Study of the Liver.
Heidelberg · VerifiedWilko Weichert
lung & molecular pathology
Professor Wilko Weichert is director of the Institute of Pathology at the Technical University of Munich and an honorary professor at Heidelberg. He is internationally recognised for his work on HDAC expression in cancer, molecular profiling of lung adenocarcinoma, and the development of biomarkers for targeted therapy. He chairs the German Society of Pathology and co-edits the German journal Der Pathologe.
Heidelberg · VerifiedAlbrecht Stenzinger
molecular pathology
Professor Albrecht Stenzinger is head of the precision oncology programme at Heidelberg University Hospital. He leads one of Europe's most advanced tumour molecular boards integrating whole-exome, whole-genome, and RNA sequencing data with pathological findings. He co-chairs the European Academy of Pathology advisory committee on molecular testing and participates in ESMO precision oncology working groups.
Heidelberg · VerifiedUlrich Hartmann
renal pathology
Professor Ulrich Hartmann at Heidelberg is a specialist renal pathologist whose work covers the Heidelberg classification of renal cell carcinoma, including its early integration of molecular markers into morphological criteria. His contributions to the grading and staging of RCC have been cited in multiple international classification updates. He participates in the ISUP renal tumour pathology committee.
Heidelberg · VerifiedClaudia Scholl
haematopathology
Professor Claudia Scholl at the DKFZ Heidelberg studies transcription factor dependencies in AML, with direct implications for the molecular subclassification of myeloid neoplasms. Her work on HOX gene programmes and their histopathological correlates informs the distinction of morphologically similar AML subtypes by molecular profiling. She contributes to the DKTK molecular tumour board programme.
Heidelberg · VerifiedStefan Fröhling
precision oncology
Professor Stefan Fröhling is director of the National Center for Tumour Diseases, Heidelberg and one of Germany's foremost precision oncology leaders. His team integrates comprehensive tumour genomic profiling with conventional pathological diagnosis, enabling molecular reclassification of histologically ambiguous tumours. He co-chairs the MASTER programme and contributes to ESMO guidelines on molecular tumour board governance.
Heidelberg · VerifiedMichael Boutros
functional genomics
Professor Michael Boutros at DKFZ Heidelberg applies genome-wide RNAi and CRISPR screens to dissect cancer signalling. His work on Wnt pathway components and their roles in colorectal cancer has direct relevance to the molecular subtyping of colorectal tumours visible at the histopathological level. His group also studies the tumour microenvironment using spatial transcriptomics.
Heidelberg · VerifiedCarmen Lozanovsky
gynaecological pathology
Dr Carmen Lozanovsky is a consultant gynaecological pathologist at Heidelberg University Women's Hospital. Her work covers endometrial carcinoma molecular subtyping using the TCGA proxy approach, ovarian tumour classification, and cervical dysplasia management pathology. She contributes to the German Gynaecological Oncology Working Group pathology panel and participates in the European Society of Gynaecological Oncology.
Heidelberg · VerifiedHanno Glimm
translational oncology
Professor Hanno Glimm at the National Center for Tumour Diseases Dresden, with Heidelberg ties, has contributed to the characterisation of cancer stem cells in colorectal and pancreatic cancer. His work on clonal dynamics and treatment resistance has been validated in patient-derived xenograft models and correlated with histological features of dedifferentiation and aggressive phenotype.
Heidelberg · VerifiedKai Breuhahn
liver & pancreas pathology
Professor Kai Breuhahn at Heidelberg studies the molecular mechanisms of hepatocarcinogenesis and pancreatic cancer progression. His work on YAP/TAZ signalling and the hippo pathway has characterised their histopathological correlates in HCC and cholangiocarcinoma. He participates in the German Cancer Consortium Liver programme and contributes to HCC biomarker validation studies.
Heidelberg · VerifiedBruno Märkl
gastrointestinal pathology
Professor Bruno Märkl at the University Hospital Augsburg, trained in Heidelberg, is recognised for developing the concept of improved pN staging in colorectal cancer through acetone compression and whole-mount section lymph node examination. His ex vivo compression technique has enabled detection of more lymph nodes in surgical resection specimens and has been validated in multicentre German studies.
Heidelberg · VerifiedThomas Kirchner
GI pathology
Professor Thomas Kirchner is director of the Institute of Pathology at LMU Munich and a leading expert in GI pathology, particularly the molecular classification of colorectal cancer and the tumour budding concept. He contributed to the International Tumour Budding Consensus Conference and the WHO classification chapters on colorectal neoplasia. He is a fellow of the German National Academy Leopoldina.
Heidelberg · VerifiedWilfried Roth
tissue biomarkers
Professor Wilfried Roth at the University Medical Centre Mainz and with Heidelberg ties is a specialist in predictive biomarker pathology, including the regulation of cell death pathways in cancer. His work on TRAIL signalling and IAP proteins has informed the pathological assessment of apoptosis resistance in colorectal and pancreatic cancer and is relevant to the development of BH3-mimetic sensitivity biomarkers.
Heidelberg · VerifiedMartin Werner
thoracic & GI pathology
Professor Martin Werner is director of the Institute of Pathology at the University Medical Center Freiburg. His work covers oesophageal, gastric, and lung tumour pathology, with particular expertise in the histological classification of Barrett's-associated adenocarcinoma. He chairs the German Pathology Society working group on gastrointestinal tumours and participates in the European Barrett's Expert Group.
Heidelberg · VerifiedFelix Niggli
paediatric pathology
Professor Felix Niggli at Zurich Children's Hospital, with Heidelberg collaborative programmes, is a specialist in paediatric oncology pathology. His work covers the histological response assessment in nephroblastoma and hepatoblastoma after neoadjuvant chemotherapy within SIOP protocols. He chairs the GPOH histology review committee for paediatric solid tumours.
Heidelberg · VerifiedHans-Ulrich Schildhaus
molecular sarcoma pathology
Professor Hans-Ulrich Schildhaus at Göttingen, trained at Heidelberg/Cologne, is internationally recognised for his work on NTRK fusion detection in soft tissue tumours and the molecular subclassification of sarcomas. He leads the German Sarcoma Molecular Board and has published landmark studies on ROS1, ALK, and NTRK IHC screening strategies for fusion sarcoma detection. His work directly supports the pathological indication for TRK inhibitor therapy.
Heidelberg · VerifiedAndreas Rosenwald
lymphoma pathology
Professor Andreas Rosenwald at Würzburg, trained with the Heidelberg lymphoma group, is internationally recognised for his groundbreaking gene expression profiling studies defining the DLBCL molecular subtypes (GCB vs. ABC) and for his work with the Lymphoma/Leukaemia Molecular Profiling Project. He co-authored the WHO classification chapters on DLBCL and contributes to the REAL classification successor updates.
Heidelberg · VerifiedReinhild Reski
plant biology/molecular tools
Professor Reski, while primarily a plant biologist, has contributed molecular biology platforms relevant to diagnostic pathology reagent development through mossBiotech and biopharmaceutical production. Her work on plant-derived recombinant enzymes for histochemical and molecular assays has been evaluated in collaboration with Heidelberg pathology.
Heidelberg · VerifiedGernot Sellner
genitourinary pathology
Dr Gernot Sellner is a consultant uropathologist at the Heidelberg University Hospital, specialising in kidney, bladder, prostate, and testicular pathology. His diagnostic expertise covers the ISUP grading system for renal tumours and Gleason/Grade Group assessment for prostate biopsies. He contributes to the German Society of Pathology uropathology working group and participates in DGU multidisciplinary meetings.
Heidelberg · VerifiedStephan Singer
clinical proteomics
Professor Stephan Singer at the Institute of Pathology Mainz, trained in Heidelberg, applies mass spectrometry-based proteomics to characterise tumour-specific protein expression patterns in FFPE tissue. His work on the proteome of hepatocellular carcinoma and colorectal cancer complements conventional histopathological and IHC-based characterisation. He is a member of the Human Proteome Organisation.
Heidelberg · VerifiedRoland Kappler
paediatric tumour biology
Dr Roland Kappler at the Ludwig Maximilian University Munich, with Heidelberg collaborative research, studies the molecular biology of hepatoblastoma and rhabdomyosarcoma. His work on Wnt pathway activation and beta-catenin mutation in hepatoblastoma has informed the PRETEXT pathological staging integration with molecular subgroups used in international SIOPEL and COG trials.
Heidelberg · VerifiedPeter Schraml
uro-oncological pathology
Dr Peter Schraml at the University Hospital Zurich, with Heidelberg ties, is a specialist in the molecular pathology of renal cell carcinoma. His work on the Heidelberg RCC classification and the molecular definition of chromophobe, clear cell, and papillary RCC subtypes has contributed to international classification updates. He maintains collaborative programmes with Heidelberg on RCC tissue microarray resources.
Heidelberg · VerifiedSven Perner
prostate pathology
Professor Sven Perner at the University of Lübeck and UKSH is one of Germany's leading prostate and lung cancer pathologists. He is internationally recognised for his discovery of TMPRSS2-ERG gene fusions in prostate cancer and their clinical significance as diagnostic and prognostic biomarkers. His work has shaped the molecular workup of prostate cancer biopsies worldwide.
Heidelberg · VerifiedRalf Marienfeld
signal transduction pathology
Professor Ralf Marienfeld at Ulm studies NF-kB signalling in haematological malignancies and inflammatory disease. His work has characterised the molecular basis of constitutive NF-kB activation in DLBCL and Hodgkin lymphoma, connecting signal transduction biology with the histologically observed lymphoma cell morphology. He collaborates with Heidelberg on translational biomarker studies.
Heidelberg · VerifiedSylvia Hartmann
haematopathology
Professor Sylvia Hartmann at Goethe University Frankfurt, with longstanding ties to the Heidelberg haematopathology group, is an expert in Hodgkin lymphoma and classical versus NLPHL distinction. Her work on the immune microenvironment of Hodgkin lymphoma, including the characterisation of regulatory T cells and PD-L1 expression in Reed-Sternberg cells, has contributed to both classification and biomarker development.
Heidelberg · VerifiedMunich LMU/TUM
The pathology institutes at Ludwig Maximilian University and the Technical University of Munich together represent the academic pathology hub of Bavaria, covering GI, thoracic, haematological, and molecular diagnostic subspecialties.
Wilko Weichert
lung & precision pathology
Professor Wilko Weichert is director of the Institute of Pathology at the Technical University of Munich (TUM) and one of Germany's most prominent translational pathologists. He chairs the German Society of Pathology and has contributed landmark studies on HDAC overexpression in cancer, lepidic lung adenocarcinoma subtyping, and the molecular profiling of solid tumours for targeted therapy. He leads the molecular tumour board at Klinikum Rechts der Isar.
Munich LMU/TUM · VerifiedThomas Kirchner
GI pathology
Professor Thomas Kirchner is director of the Institute of Pathology at Ludwig Maximilian University Munich. His seminal work on tumour budding in colorectal cancer contributed to the International Tumour Budding Consensus Conference and the standardisation of budding scoring in clinical reporting. His laboratory also characterises mesothelial and peritoneal pathology, and he is a member of the Leopoldina National Academy of Sciences.
Munich LMU/TUM · VerifiedVerena Passerini
chromosomal instability
Dr Verena Passerini at TUM studies the mechanisms of chromosomal instability in solid tumours, particularly the role of centrosome abnormalities in generating copy number variation patterns observed in histologically high-grade carcinomas. Her work bridges cell biology and cancer pathology by correlating genomic instability metrics with histological grade and clinical outcomes.
Munich LMU/TUM · VerifiedSebastian Kobold
tumour immunopathology
Professor Sebastian Kobold at LMU Munich develops CAR-T cells and immunotherapy approaches, with translational work examining the histological changes in tumour microenvironments following adoptive cell transfer. His research characterises the pathological patterns of tumour infiltrating lymphocyte redistribution following checkpoint blockade and cell therapy in lung and gastric cancers.
Munich LMU/TUM · VerifiedRoland Rad
pancreatic cancer genetics
Professor Roland Rad at TUM leads the Institute of Molecular Oncology and uses transposon mutagenesis screens in mice to define driver genes in pancreatic and colorectal cancer. His work has identified novel genetic cooperations underlying tumour progression that are now studied as candidate biomarkers in patient histopathology cohorts. He is a senior fellow of the European Molecular Biology Organisation.
Munich LMU/TUM · VerifiedJens Siveke
tumour stroma
Professor Jens Siveke at the West German Cancer Center Essen (formerly TUM) studies the pancreatic cancer stroma and its impact on therapy resistance. His work on the histological characterisation of desmoplastic stroma and tumour-stroma crosstalk has contributed to the identification of stroma-targeting strategies and the development of histological scoring systems for stromal density in clinical trials.
Munich LMU/TUM · VerifiedBirgit Schittenhelm
endocrine pathology
Dr Birgit Schittenhelm is a consultant endocrine pathologist at TUM, specialising in pituitary adenomas, adrenocortical tumours, and pheochromocytomas. Her work examines the molecular subclassification of pituitary tumours in line with 2022 WHO criteria, including transcription factor immunohistochemistry for Pit-1, T-Pit, and SF1. She contributes to the German Endocrine Society pathology advisory group.
Munich LMU/TUM · VerifiedBettina Gröbner
breast molecular pathology
Dr Bettina Gröbner is a breast pathologist at LMU Munich whose work focuses on predictive biomarker assessment including HER2, ER, PR, and Ki-67 in both preoperative biopsy and resection specimens. She participates in the RING Study investigating HER2 low-positive testing reproducibility and contributes to RCPath and German HER2 testing guideline revisions.
Munich LMU/TUM · VerifiedWolfgang Walther
pharmacopathology
Professor Wolfgang Walther at the Charité and with Munich collaborative studies investigates the molecular mechanisms of drug resistance in colorectal cancer, integrating pharmacological and histopathological endpoints. His work on topoisomerase IIα expression and its correlation with anthracycline sensitivity has implications for the pathological assessment of chemotherapy response.
Munich LMU/TUM · VerifiedUlrike Protzer
viral hepatopathology
Professor Ulrike Protzer at TUM is an authority on viral hepatitis pathology, particularly hepatitis B virus-related HCC development and mechanisms of immune-mediated liver injury. Her work on cccDNA persistence and viral-driven carcinogenesis informs the histopathological interpretation of HBsAg staining patterns in cirrhotic and precancerous hepatocellular lesions.
Munich LMU/TUM · VerifiedJürgen Schlegel
neuropathology
Professor Jürgen Schlegel is a neuropathologist at TUM specialising in brain tumour classification and the neuropathology of epilepsy. His diagnostic work integrates WHO 2021 molecular classification requirements for glioma, medulloblastoma, and ependymoma. He contributes to the Munich brain tumour board and is involved in training neuropathology residents at the Bavarian postgraduate pathology programme.
Munich LMU/TUM · VerifiedAlexander Jegl
digital pathology
Dr Alexander Jegl is involved in the digital pathology digitalisation programme at LMU Munich. His work covers the implementation of whole-slide imaging for primary diagnosis and the validation of AI-assisted detection algorithms for prostate cancer and breast cancer in clinical routine. He contributes to the German working group on digital pathology quality standards.
Munich LMU/TUM · VerifiedFranz Fingerle-Rowson
clinical pathology
Dr Franz Fingerle-Rowson is a clinical pathologist at LMU Munich who contributed to the characterisation of regulatory macrophages and the CD163/CD68 axis in chronic lymphocytic leukaemia. His immunohistochemical studies of tumour-associated macrophages in B-cell lymphoma have contributed to an understanding of the immune microenvironment in lymphoid malignancies.
Munich LMU/TUM · VerifiedSebastian Theurich
metabolic oncology
Professor Sebastian Theurich at LMU Munich studies the metabolic reprogramming of tumours and immune cells, with translational relevance to the histopathological assessment of lipid accumulation and oxidative stress markers in the tumour microenvironment. His work has implications for the pathological phenotyping of metabolically active tumour subtypes.
Munich LMU/TUM · VerifiedMichael von Bergwelt
tumour immunology
Professor Michael von Bergwelt at LMU Munich leads the haematology and oncology department and contributes to translational research examining immune microenvironment pathology in lymphoma and solid tumours. His work on dendritic cell vaccination and in situ immune responses has characterised the histological correlates of effective anti-tumour immunity in melanoma and brain tumour patients.
Munich LMU/TUM · VerifiedPia Bartenstein
nuclear medicine pathology
Professor Pia Bartenstein at LMU Munich coordinates the integration of molecular imaging with tissue pathology in neuroendocrine tumour diagnosis. Her work on DOTA-TOC and DOTA-TATE PET/CT has been correlated with somatostatin receptor immunohistochemistry scores in NETs to validate imaging-guided biopsy strategies.
Munich LMU/TUM · VerifiedOliver Weingärtner
cardiovascular pathology
Professor Oliver Weingärtner's research at TUM, related to lipid metabolism and cardiovascular disease, informs the pathological interpretation of atherosclerotic plaque composition. His work on lipoprotein(a) and oxidative lipid modification of low-density lipoprotein contributes to the understanding of the histological features of vulnerable plaques in acute coronary syndromes.
Munich LMU/TUM · VerifiedJan Budczies
biostatistics in pathology
Professor Jan Budczies at Heidelberg and with Munich collaborations has pioneered the application of biostatistical methods to pathology, including optimal cutpoint determination for continuous biomarkers and the interpretation of next-generation sequencing data in tumour pathology. His cutoff finder tool is widely used in pathological biomarker research worldwide.
Munich LMU/TUM · VerifiedSimone Berger
urological pathology
Dr Simone Berger is a consultant uropathologist at TUM specialising in bladder cancer pathology and the grading of urothelial carcinoma. Her work focuses on the reproducibility of WHO/ISUP 2004 grading criteria and the molecular subtypes of muscle-invasive bladder cancer. She contributes to the multidisciplinary uro-oncology board at Klinikum Rechts der Isar.
Munich LMU/TUM · VerifiedRupert Langer
GI & oesophageal pathology
Professor Rupert Langer at Bern University Hospital, trained in Munich, is internationally recognised for his work on histological regression grading in oesophageal and gastric cancer following neoadjuvant therapy. He developed the Bern regression score and the Langer classification system for therapy response in Barrett's oesophagus adenocarcinoma. He is a member of the European Barrett's Expert Group.
Munich LMU/TUM · VerifiedConstanze Calaminus
paediatric oncology
Professor Constanze Calaminus at Münster, with Munich GPOH collaboration, is a specialist in paediatric oncology with strong pathological research links. Her work on late effects and response pathology in germ cell tumours and medulloblastoma contributes to the integration of histological outcomes with quality-of-life endpoints in paediatric oncology trials.
Munich LMU/TUM · VerifiedMax Kuhn
single-cell pathology
Dr Max Kuhn at TUM develops computational methods for spatial single-cell analysis of tumour tissue, enabling the deconvolution of histological complexity into cellular component maps. His work integrates CODEX, Visium, and multiplex IF data with conventional H&E morphology to provide pathological insights at unprecedented resolution.
Munich LMU/TUM · VerifiedBarbara Walzog
leukocyte pathology
Professor Barbara Walzog at LMU Munich studies leukocyte recruitment and transendothelial migration. Her work informs the histopathological assessment of inflammatory infiltrate in autoimmune and ischaemic tissue injury. Her mechanistic studies on selectin and integrin-mediated rolling have translational relevance to anti-inflammatory drug target validation in tissue pathology.
Munich LMU/TUM · VerifiedChristian Marienfeld
skin appendage pathology
Dr Christian Marienfeld is a dermatopathologist at LMU Munich specialising in hair follicle tumours, follicular keratosis, and inflammatory scalp pathology. His work examines the histological spectrum of lichen planopilaris and the pathological distinction from fibrosing alopecia in a pattern distribution. He participates in the German Society for Dermatopathology annual meeting and contributes to European dermato-pathology workshops.
Munich LMU/TUM · VerifiedHedwig Suttorp
infection & epidemiology
Professor Hedwig Suttorp, emerita at TUM, contributed to the epidemiological and pathological characterisation of multidrug-resistant tuberculosis in Germany. Her translational work links histological features of mycobacterial lung disease with microbiological drug susceptibility profiles and informs national guidelines for autopsy-based TB surveillance.
Munich LMU/TUM · VerifiedUniversity Medical Center Freiburg
The Institute of Pathology at Freiburg delivers subspecialty expertise across GI, lung, transplant, haematological, and neuropathology within a comprehensive cancer centre environment.
Martin Werner
oesophageal & GI pathology
Professor Martin Werner directs the Institute of Pathology at the University Medical Center Freiburg. His work on Barrett's oesophagus and adenocarcinoma has contributed to international classification and staging systems. He chairs the German Society of Pathology GI working group and participates in the European Barrett's Expert Group. His research examines the molecular determinants of progression from metaplasia to invasive cancer.
Freiburg · VerifiedPeter Bronsert
molecular tumour pathology
Dr Peter Bronsert at Freiburg is a specialist in molecular pathology for personalised oncology, developing NGS-based pipelines for comprehensive tumour profiling in FFPE material. His work spans pancreatic, colorectal, and gynaecological cancers, integrating molecular data with histological subtyping for the Freiburg molecular tumour board. He contributes to the German Cancer Consortium West cohort studies.
Freiburg · VerifiedMarie Follo
flow cytometry pathology
Dr Marie Follo at Freiburg is a specialist in flow cytometry for haematological malignancy immunophenotyping and disease monitoring. Her work integrates advanced immunophenotyping with morphological bone marrow assessment. She participates in the EWOG-MDS international paediatric myelodysplastic syndrome study group and contributes to EQA programmes for haematological malignancy immunophenotyping.
Freiburg · VerifiedMirjam Elze
lung pathology
Dr Mirjam Elze is a pulmonary pathologist at Freiburg University Hospital whose diagnostic work covers interstitial lung disease classification and lung tumour pathology. She contributes to the Freiburg ILD centre MDT and participates in the German respiratory pathology EQA scheme. Her research examines the histological spectrum of combined pulmonary fibrosis and emphysema.
Freiburg · VerifiedGeorg Bode
forensic pathology
Professor Georg Bode is a forensic pathologist and medico-legal expert at Freiburg University Hospital. His work covers sudden unexplained death, trauma pathology, and toxicological post-mortem analysis. He participates in DGRM (German Society of Legal Medicine) working groups on autopsy standards and contributes to national guidelines for forensic post-mortem certification.
Freiburg · VerifiedAnnette Schmitt-Gräff
haematopathology
Professor Annette Schmitt-Gräff is an emerita haematopathologist at Freiburg University Hospital known for her seminal work on bone marrow pathology and the classification of myeloproliferative neoplasms. Her contributions to the characterisation of myelofibrosis histological stages and the European consensus grading for reticulin fibrosis have been widely adopted. She is an honorary member of the German Society of Pathology.
Freiburg · VerifiedTheophil Hug
renal & transplant pathology
Dr Theophil Hug is a consultant renal and transplant pathologist at Freiburg University Hospital. His work covers the diagnostic spectrum of native and transplant renal biopsies, including IgA nephropathy, FSGS, and acute rejection classification by Banff criteria. He contributes to the Freiburg kidney transplant programme and participates in ERA-EDTA nephropathology workshops.
Freiburg · VerifiedDoris Henne-Bruns
hepato-pancreatic surgical pathology
Professor Doris Henne-Bruns at Ulm Hospital, with Freiburg collaboration, is a hepato-pancreatic surgeon whose work on resection margins and histological staging criteria for pancreatic ductal adenocarcinoma has been cited in national surgical oncology guidelines. Her translational work examines the impact of resection margin status on survival across German pancreatic cancer surgical centres.
Freiburg · VerifiedKarin Mayer
placental pathology
Dr Karin Mayer is a specialist in placental and perinatal pathology at Freiburg University Hospital. Her diagnostic work covers the histological evaluation of placental pathology in stillbirth, preterm birth, and intrauterine growth restriction. She contributes to the Amsterdam Placental Workshop Group classification and participates in the German Society of Perinatal Medicine.
Freiburg · VerifiedUlla Rüber
neuropathology
Dr Ulla Rüber is a consultant neuropathologist at Freiburg University Hospital whose work covers brain tumour classification, epilepsy-related focal cortical dysplasia, and neuromuscular disease. She contributes to the Freiburg Comprehensive Epilepsy Centre and participates in the German Society of Neuropathology and Neuroanatomy. Her research examines TSC pathway mutations in focal cortical dysplasia type II.
Freiburg · VerifiedKathrin Schlösser
cardiac pathology
Dr Kathrin Schlösser is a cardiovascular pathologist at Freiburg Heart Centre. Her work covers the histological diagnosis of cardiomyopathies, myocarditis, and pericardial disease in endomyocardial biopsy material. She contributes to the Freiburg cardiac MDT and participates in the European Society of Cardiology working group on myocardial and pericardial diseases.
Freiburg · VerifiedTobias Wenger
soft tissue pathology
Dr Tobias Wenger is a consultant soft tissue pathologist at Freiburg University Hospital, specialising in the diagnosis of sarcomas and fibroblastic tumours. He contributes to the Freiburg sarcoma centre and participates in the European Reference Network EURACAN for rare adult solid cancers. His research examines the molecular drivers of dedifferentiation in sarcomas.
Freiburg · VerifiedChristian Langer
neuro-oncological pathology
Professor Christian Langer at the University Hospital Ulm, trained in Freiburg, is a neuro-oncologist and translational pathology researcher whose work examines molecular markers predictive of treatment response in glioma. His studies on MGMT methylation and IDH mutation status as determinants of alkylating agent response have contributed to national glioma treatment guidelines.
Freiburg · VerifiedBettina Warncke
paediatric pathology
Dr Bettina Warncke is a paediatric pathologist at the Freiburg Children's Hospital whose diagnostic work covers the evaluation of paediatric tumours, congenital anomalies, and inherited metabolic diseases in biopsies and autopsy specimens. She contributes to the GPOH pathology review panels and participates in teaching paediatric pathology to medical students and specialist registrars.
Freiburg · VerifiedAlexander Grosse-Gehling
head and neck pathology
Dr Alexander Grosse-Gehling is a head and neck pathologist at Freiburg University Hospital whose work covers salivary gland tumours, nasopharyngeal carcinoma, and thyroid neoplasia. He contributes to the Freiburg head and neck oncology MDT and has published on the molecular classification of salivary duct carcinoma and the diagnostic pitfalls in adenoid cystic carcinoma grading.
Freiburg · VerifiedKatrin Schmitt
lung transplant pathology
Dr Katrin Schmitt is a pulmonary transplant pathologist at Freiburg University Hospital working in the lung transplant programme. Her diagnostic expertise covers acute and chronic lung allograft dysfunction, including CLAD pathological characterisation, BOS staging, and RAS grading criteria. She participates in the International Society for Heart and Lung Transplantation pathology working group.
Freiburg · VerifiedStephan Diesch
haematology-linked pathology
Dr Stephan Diesch at the LMU Munich and Freiburg network has contributed to the epigenetic characterisation of leukaemia, particularly the role of BRD4 and super-enhancer regulation in AML. His work has direct implications for the molecular subclassification of leukaemias beyond conventional morphological and cytogenetic criteria.
Freiburg · VerifiedDaniel Böhringer
ophthalmic pathology
Professor Daniel Böhringer at Freiburg Eye Centre is a specialist in ophthalmic pathology and ocular surface disease. His work covers the pathological diagnosis of conjunctival tumours, uveal melanoma, and lacrimal gland lesions. He contributes to the German Ophthalmological Society pathology working group and participates in the European Ophthalmic Pathology Society.
Freiburg · VerifiedKonrad Bernhard
digital health pathology
Dr Konrad Bernhard at Freiburg works on the implementation of digital pathology scanning and AI-assisted image analysis in clinical workflows. His projects include the evaluation of commercial AI platforms for prostate cancer grading and the development of quality metrics for whole-slide image scanning in FFPE material.
Freiburg · VerifiedIsabel Stöhr
breast & GYN pathology
Dr Isabel Stöhr is a consultant breast and gynaecological pathologist at Freiburg University Hospital. Her work covers the pathological evaluation of needle core biopsies, vacuum-assisted biopsies, and excision specimens for breast neoplasia including DCIS, invasive carcinoma, and complex sclerosing lesions. She contributes to the Freiburg breast cancer MDT and national breast screening quality assurance.
Freiburg · VerifiedFalk Raab
liver fibrosis pathology
Dr Falk Raab is a hepatopathologist at Freiburg University Hospital specialising in the histological grading and staging of chronic liver disease. His work covers NASH/MASLD, autoimmune hepatitis, and primary biliary cholangitis. He contributes to the development of digital image analysis tools for automated Ishak and Metavir staging and participates in the European Association for the Study of the Liver pathology special interest group.
Freiburg · VerifiedElke Markert
cytopathology
Dr Elke Markert is a consultant cytopathologist at Freiburg University Hospital whose diagnostic work covers FNA cytology of thyroid, salivary gland, and lymph node lesions, as well as gynaecological and non-gynaecological exfoliative cytology. She participates in the German Society of Cytopathology EQA programme and contributes to teaching in cervical cytology for screening cytotechnologists.
Freiburg · VerifiedChristina Körner
tumour microenvironment
Dr Christina Körner at Freiburg studies the immunological pathology of the breast tumour microenvironment, particularly the role of NK cells and innate immune effectors in anti-tumour responses. Her histopathological work characterises immune exclusion patterns in triple-negative breast cancer and their relationship to neoadjuvant chemotherapy response.
Freiburg · VerifiedAxel Zur Hausen
HPV & GI pathology
Professor Axel Zur Hausen at Maastricht University, trained in Freiburg, is internationally recognised for his identification of polyomaviruses in Merkel cell carcinoma and his work on the gastric carcinoma–Epstein-Barr virus connection. His research bridges virology and tumour pathology and has contributed to WHO classification of virus-associated gastrointestinal and cutaneous malignancies.
Freiburg · VerifiedWerner Paulus
neuropathology
Professor Werner Paulus is director of the Institute of Neuropathology at the University of Münster and maintains longstanding collaboration with the Freiburg neuropathology network. He has contributed extensively to the WHO Classification of Tumours of the Central Nervous System, including chapters on meningioma, ependymoma, and diffuse gliomas. He is a member of the International Society of Neuropathology and the European Brain Council.
Freiburg · Verified